The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s antisense & RNAi therapeutics market report forecasts the antisense & RNAi therapeutics market size to grow to $2.42 Billion by 2027, with a CAGR (compound annual growth rate) of 12%.

Learn More On The Antisense & RNAi Therapeutics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Antisense & RNAi Therapeutics Market Size Forecast
The global antisense & RNAi therapeutics market is expected to grow from $1.42 billion in 2022 to $1.54 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antisense & RNAi therapeutics market is expected to grow from $2.42 billion in 2027 at a CAGR of 12.0%.

North America held the largest antisense & RNAi therapeutics market share.

Key Antisense & RNAi Therapeutics Market Driver ­– Rise In The Prevalence Of Coronary Artery Diseases, Neurodegenerative Disorders, And Infectious Diseases
According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases affecting millions of people globally. In the USA, around 930,000 people had Parkinson’s disease by the end of 2020. Furthermore, according to the World Health Organization (WHO), infectious diseases are a major concern and dominated the WHO’s list of health threats ranging from various climate change issues to inadequate healthcare facilities. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.

Request for A Sample Of The Global Antisense & RNAi Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

Key Antisense & RNAi Therapeutics Market Trend – Undertaking Strategic Initiatives
Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2020, Aro Biotherapeutics Company has announced a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the market leader in RNA-targeted therapeutics, under which Ionis will use Aro’s CENTYRINTM technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs).

Antisense & RNAi Therapeutics Market Segment
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Antisense & RNAi Therapeutics Market Major Players and Strategies
Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline PLC., Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd.

In December 2021, AstraZeneca PLC., a UK-based pharmaceutical and biotechnology company, announced a strategic partnership with Ionis Pharmaceuticals, Inc., a US-based biopharmaceutical company pioneering in the discovery and development of RNA-based therapeutics and drugs. Under this strategic partnership, Eplontersen will be developed and commercialized by the two businesses together in the US and by AstraZeneca in all other regions outside of Latin America.

The Antisense & RNAi Therapeutics Global Market Report 2023 covers regional data on antisense & RNAi therapeutics market size, antisense & RNAi therapeutics market trends and drivers, opportunities, strategies, and antisense & RNAi therapeutics market competitor analysis. The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.

View More Reports Related To The Antisense & RNAi Therapeutics Market –
Digital Therapeutics Global Market Report 2023
AntiHypertensive Drugs Global Market Report 2023
Leukemia Therapeutics Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: